Daré Bioscience, Inc. (DARE) News

Daré Bioscience, Inc. (DARE): $1.08

0.02 (+2.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DARE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 392

in industry

Filter DARE News Items

DARE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DARE News Highlights

  • DARE's 30 day story count now stands at 2.
  • Over the past 10 days, the trend for DARE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about DARE are BIO and DECK.

Latest DARE News From Around the Web

Below are the latest news stories about Dare Bioscience Inc that investors may wish to consider to help them evaluate DARE as an investment opportunity.

Daré Bioscience (DARE) Investor Presentation - Slideshow

The following slide deck was published by Daré Bioscience, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | February 17, 2022

Daré Bioscience to Participate in Upcoming Conferences

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming conferences: 2022 BIO CEO & Investor ConferenceFebruary 14-17, 2022, New York Marriott Marquis and VirtualIn-person Presentation Monday, February 14, 2022 at 2:15 p.m. EST SVB Leerink Virtual 11th Annual Global Healthcare ConferenceFebruary 14-1

Yahoo | February 7, 2022

Analysts Have Conflicting Sentiments on These Healthcare Companies: Zogenix (ZGNX) and Daré Bioscience (DARE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zogenix (ZGNX – Research Report) and Daré Bioscience (DARE – Research Report). Zogenix (ZGNX) In a report released today, Serge Belanger from Needham downgraded Zogenix to Hold. The company's shares closed last Wednesday at $26.19. According to TipRanks.

Brian Anderson on TipRanks | January 19, 2022

Dawson James Remains a Buy on Daré Bioscience (DARE)

Dawson James analyst Jason Kolbert maintained a Buy rating on Daré Bioscience (DARE – Research Report) on November 23 and set a price target of $3.00. The company's shares closed last Thursday at $1.84. According to TipRanks.com, Kolbert is a 4-star analyst with an average return of 5.0% and a 41.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Daré Bioscience with a $3.67 average price target, a 102.8% upside from current levels.

Brian Anderson on TipRanks | January 7, 2022

Dawson James Sticks to Their Buy Rating for Daré Bioscience (DARE)

Dawson James analyst Jason Kolbert maintained a Buy rating on Daré Bioscience (DARE – Research Report) on December 8 and set a price target of $3.00. The company's shares closed last Thursday at $1.84. According to TipRanks.com, Kolbert is a 4-star analyst with an average return of 5.0% and a 41.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. Daré Bioscience has an analyst consensus of Strong Buy, with a price target consensus of $3.67, implying a 102.8% upside from current levels. In a report issued on December 8, H.C.

Christine Brown on TipRanks | January 7, 2022

Daré Bioscience to Participate in H.C. Wainwright BIOCONNECT 2022 Conference

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright BIOCONNECT 2022 Conference being held virtually January 10 – 13, 2022. Ms. Johnson’s presentation will be available on-demand for conference participants, and under “Presentations, Events & Webcasts" in the Investors section of t

Yahoo | January 4, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | December 9, 2021

Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis

Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.

Yahoo | December 9, 2021

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), MiMedx Group (MDXG) and Daré Bioscience (DARE)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neurocrine (NBIX – Research Report), MiMedx Group (MDXG – Research Report) and Daré Bioscience (DARE – Research Report) with bullish sentiments. Neurocrine (NBIX) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Neurocrine today and set a price target of $140.00. The company's shares closed last Tuesday at $82.25, close to its 52-week low of $78.31. According to TipRanks.

Brian Anderson on TipRanks | December 8, 2021

Penny Stocks to Watch: What’s Going on With ZOM, DARE, PSFE, EFOI and AUUD Today?

Penny stocks are still a hot topic among retail traders and we're covering some of the top ones to watch Wednesday that are on the move.

William White on InvestorPlace | December 8, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5612 seconds.